Recent Developments in LRRK2-Targeted Therapy for Parkinson’s Disease

Induced pluripotent stem cell-based modeling of mutant LRRK2-associated Parkinson's Disease

(2019) Beatrice Weykopf et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

LRRK2 impairs PINK1/Parkin-dependent mitophagy via its kinase activity: pathologic insights into Parkinson’s disease

(2019) Fiona Bonello et al.   HUMAN MOLECULAR GENETICS

LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients

(2019) Farzaneh Atashrazm et al.   MOVEMENT DISORDERS

LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice

(2019) Michael X. Henderson et al.   Acta Neuropathologica Communications

Parkinson's disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology

(2018) Tetta Fujimoto et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human

(2018) Rafeeq Mir et al.   BIOCHEMICAL JOURNAL

Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo

(2018) Elena Kozina et al.   BRAIN

LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages

(2018) Anetta Härtlova et al.   EMBO JOURNAL

Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV-α-synuclein is normalized by LRRK2 modulation

(2018) Michael Aagaard Andersen et al.   NEUROBIOLOGY OF DISEASE

Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice

(2018) Yulan Xiong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats

(2018) Michael Aagaard Andersen et al.   TOXICOLOGY

G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice

(2018) Salvatore Novello et al.   NEUROBIOLOGY OF DISEASE

LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis

(2018) Tomoya Eguchi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

LRRK2 activation in idiopathic Parkinson’s disease

(2018) Roberto Di Maio et al.   Science Translational Medicine

LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation

(2018) Eun-Jin Bae et al.   Nature Communications

Reduced glucocerebrosidase activity in monocytes from patients with Parkinson’s disease

(2018) Farzaneh Atashrazm et al.   Scientific Reports

The role of LRRK2 in cell signalling

(2018) Kirsten Harvey et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review

(2018) Joanne Trinh et al.   MOVEMENT DISORDERS

RAB7L1-Mediated Relocalization of LRRK2 to the Golgi Complex Causes Centrosomal Deficits via RAB8A

(2018) Jesús Madero-Pérez et al.   Frontiers in Molecular Neuroscience

Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease

(2017) Andrew B. West   EXPERIMENTAL NEUROLOGY

Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016)

(2017) Paul Galatsis   EXPERT OPINION ON THERAPEUTIC PATENTS

LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease

(2017) Evan H Howlett et al.   HUMAN MOLECULAR GENETICS

LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network

(2017) Zhiyong Liu et al.   HUMAN MOLECULAR GENETICS

Vps35 in cooperation with LRRK2 regulates synaptic vesicle endocytosis through the endosomal pathway in Drosophila

(2017) Tsuyoshi Inoshita et al.   HUMAN MOLECULAR GENETICS

LRRK2 promotes the activation of NLRC4 inflammasome duringSalmonellaTyphimurium infection

(2017) Weiwei Liu et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity

(2017) Jack D. Scott et al.   JOURNAL OF MEDICINAL CHEMISTRY

Synthesis and In Vitro and In Vivo Evaluation of [3H]LRRK2-IN-1 as a Novel Radioligand for LRRK2

(2017) Noeen Malik et al.   MOLECULAR IMAGING AND BIOLOGY

Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles

(2017) Stefanie Lerche et al.   MOVEMENT DISORDERS

The pathogenic LRRK2 R1441C mutation induces specific deficits modeling the prodromal phase of Parkinson's disease in the mouse

(2017) F. Giesert et al.   NEUROBIOLOGY OF DISEASE

Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice

(2017) Mattia Volta et al.   eLife

Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis

(2017) Martin Steger et al.   eLife

Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice

(2017) Francesco Longo et al.   Acta Neuropathologica Communications

Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells

(2017) Kenneth Thirstrup et al.   Scientific Reports

Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors

(2016) G. Ito et al.   BIOCHEMICAL JOURNAL

Functional Impairment in Miro Degradation and Mitophagy Is a Shared Feature in Familial and Sporadic Parkinson’s Disease

(2016) Chung-Han Hsieh et al.   Cell Stem Cell

Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission

(2016) Qi Qin et al.   CNS Neuroscience & Therapeutics

Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance

(2016) Dena G. Hernandez et al.   JOURNAL OF NEUROCHEMISTRY

G2019S-LRRK2 Expression Augments  -Synuclein Sequestration into Inclusions in Neurons

(2016) L. A. Volpicelli-Daley et al.   JOURNAL OF NEUROSCIENCE

Genetics of Parkinson's disease

(2016) Christina M. Lill   MOLECULAR AND CELLULAR PROBES

LRRK2 Expression Is Deregulated in Fibroblasts and Neurons from Parkinson Patients with Mutations in PINK1

(2016) Garikoitz Azkona et al.   MOLECULAR NEUROBIOLOGY

LRRK2 at the interface of autophagosomes, endosomes and lysosomes

(2016) Dorien A. Roosen et al.   Molecular Neurodegeneration

Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers

(2016) Nicolas Dzamko et al.   MOVEMENT DISORDERS

Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease

(2016) Kyle B. Fraser et al.   MOVEMENT DISORDERS

Arm swing as a potential new prodromal marker of Parkinson's disease

(2016) Anat Mirelman et al.   MOVEMENT DISORDERS

LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies

(2016) Nicolas Dzamko et al.   MOVEMENT DISORDERS

Leucine-Rich Repeat Kinase 2 Influences Fate Decision of Human Monocytes Differentiated from Induced Pluripotent Stem Cells

(2016) Anna Speidel et al.   PLoS One

Inhibitor treatment of peripheral mononuclear cells from Parkinson’s disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker

(2016) G. Perera et al.   Scientific Reports

Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases

(2016) Martin Steger et al.   eLife

LRRK2 contributes to monocyte dysregulation in Parkinson’s disease

(2016) Corinna Bliederhaeuser et al.   Acta Neuropathologica Communications

Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease

(2015) Ziv Gan-Or et al.   Autophagy

Glucocerebrosidase activity in Parkinson’s disease with and withoutGBAmutations

(2015) Roy N. Alcalay et al.   BRAIN

LRRK2 Pathways Leading to Neurodegeneration

(2015) Mark R. Cookson   Current Neurology and Neuroscience Reports

Phosphoproteomic screening identifies Rab GTPases as novel downstream targets of PINK1

(2015) Y.-C. Lai et al.   EMBO JOURNAL

VPS35pathogenic mutations confer no dominant toxicity but partial loss of function inDrosophilaand genetically interact withparkin

(2015) Bilal R. Malik et al.   HUMAN MOLECULAR GENETICS

Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression

(2015) Anastasia G. Henry et al.   HUMAN MOLECULAR GENETICS

14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening

(2015) Nicholas J. Lavalley et al.   HUMAN MOLECULAR GENETICS

Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration

(2015) João P. L. Daher et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Parkinson's disease

(2015) Lorraine V Kalia et al.   LANCET

Fibroblast Biomarkers of Sporadic Parkinson’s Disease and LRRK2 Kinase Inhibition

(2015) G. A. Smith et al.   MOLECULAR NEUROBIOLOGY

DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease

(2015) Alberto Bergareche et al.   MOVEMENT DISORDERS

Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in theLRRK2gene

(2015) Anat Mirelman et al.   MOVEMENT DISORDERS

Age-specific penetrance ofLRRK2G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium

(2015) Karen Marder et al.   NEUROLOGY

Effect of selective LRRK2 kinase inhibition on nonhuman primate lung

(2015) Reina N. Fuji et al.   Science Translational Medicine

Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor

(2015) John M. Hatcher et al.   ACS Medicinal Chemistry Letters

Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson’s Disease-Related LRRK2 G2019S Mutation

(2015) Andrew J. Schwab et al.   Stem Cell Reports

Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease

(2014) Karen E. Murphy et al.   BRAIN

Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy

(2014) J. Schapansky et al.   HUMAN MOLECULAR GENETICS

Discovery and Preclinical Profiling of 3-[4-(Morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a Highly Potent, Selective, Brain Penetrant, and in Vivo Active LRRK2 Kinase Inhibitor

(2014) Jaclyn L. Henderson et al.   JOURNAL OF MEDICINAL CHEMISTRY

LRRK2 pathobiology in Parkinson's disease

(2014) Ian Martin et al.   JOURNAL OF NEUROCHEMISTRY

Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease

(2014) A. Beilina et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutation in VPS35 associated with Parkinson’s disease impairs WASH complex association and inhibits autophagy

(2014) Eszter Zavodszky et al.   Nature Communications

Phosphorylation of LRRK2 by casein kinase 1α regulates trans-Golgi clustering via differential interaction with ARHGEF7

(2014) Ruth Chia et al.   Nature Communications

Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle

(2013) Evy Lobbestael et al.   BIOCHEMICAL JOURNAL

Discovery of Highly Potent, Selective, and Brain-Penetrant Aminopyrazole Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors

(2013) Anthony A. Estrada et al.   JOURNAL OF MEDICINAL CHEMISTRY

Interplay of LRRK2 with chaperone-mediated autophagy

(2013) Samantha J Orenstein et al.   NATURE NEUROSCIENCE

Advances in the genetics of Parkinson disease

(2013) Joanne Trinh et al.   Nature Reviews Neurology

RAB7L1 Interacts with LRRK2 to Modify Intraneuronal Protein Sorting and Parkinson’s Disease Risk

(2013) David A. MacLeod et al.   NEURON

LRRK2 and RIPK2 Variants in the NOD 2-Mediated Signaling Pathway Are Associated with Susceptibility to Mycobacterium leprae in Indian Populations

(2013) Patrick Marcinek et al.   PLoS One

Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs

(2013) Marco A. S. Baptista et al.   PLoS One

Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3

(2013) K. Muda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The genetics and neuropathology of Parkinson’s disease

(2012) Henry Houlden et al.   ACTA NEUROPATHOLOGICA

The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation

(2012) Iakov N. Rudenko et al.   BIOCHEMICAL JOURNAL

GSK2578215A; A potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor

(2012) Alastair D. Reith et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Neurodegenerative phenotypes in an A53T  -synuclein transgenic mouse model are independent of LRRK2

(2012) J. P. L. Daher et al.   HUMAN MOLECULAR GENETICS

Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity

(2012) C. Yao et al.   HUMAN MOLECULAR GENETICS

The retromer complex - endosomal protein recycling and beyond

(2012) M. N. J. Seaman   JOURNAL OF CELL SCIENCE

Discovery of Highly Potent, Selective, and Brain-Penetrable Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors

(2012) Anthony A. Estrada et al.   JOURNAL OF MEDICINAL CHEMISTRY

LRRK2 Inhibition Attenuates Microglial Inflammatory Responses

(2012) M. S. Moehle et al.   JOURNAL OF NEUROSCIENCE

Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway

(2012) Youren Tong et al.   Molecular Neurodegeneration

Systematic Review and UK-Based Study ofPARK2 (parkin), PINK1, PARK7 (DJ-1)andLRRK2in early-onset Parkinson's disease

(2012) Laura L. Kilarski et al.   MOVEMENT DISORDERS

Progressive degeneration of human neural stem cells caused by pathogenic LRRK2

(2012) Guang-Hui Liu et al.   NATURE

Large-scale replication and heterogeneity in Parkinson disease genetic loci

(2012) M. Sharma et al.   NEUROLOGY

Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers

(2012) M. Anheim et al.   NEUROLOGY

LRRK2 I2020T mutation is associated with tau pathology

(2012) Sachiko Ujiie et al.   PARKINSONISM & RELATED DISORDERS

The IkappaB Kinase Family Phosphorylates the Parkinson’s Disease Kinase LRRK2 at Ser935 and Ser910 during Toll-Like Receptor Signaling

(2012) Nicolas Dzamko et al.   PLoS One

Gaucher disease gene GBA functions in immune regulation

(2012) J. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ser1292 Autophosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations

(2012) Z. Sheng et al.   Science Translational Medicine

Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson's Disease

(2012) O. Cooper et al.   Science Translational Medicine

Brain Penetrant LRRK2 Inhibitor

(2012) Hwan Geun Choi et al.   ACS Medicinal Chemistry Letters

Chemoproteomics-Based Design of Potent LRRK2-Selective Lead Compounds That Attenuate Parkinson’s Disease-Related Toxicity in Human Neurons

(2011) Nigel Ramsden et al.   ACS Chemical Biology

A Mutation in VPS35, Encoding a Subunit of the Retromer Complex, Causes Late-Onset Parkinson Disease

(2011) Alexander Zimprich et al.   AMERICAN JOURNAL OF HUMAN GENETICS

VPS35 Mutations in Parkinson Disease

(2011) Carles Vilariño-Güell et al.   AMERICAN JOURNAL OF HUMAN GENETICS

LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice

(2011) Martin C. Herzig et al.   HUMAN MOLECULAR GENETICS

Parkinson’s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures

(2011) Mansoureh Hakimi et al.   JOURNAL OF NEURAL TRANSMISSION

Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson’s disease mutations and LRRK2 pharmacological inhibition

(2011) Elizabeth A. Doggett et al.   JOURNAL OF NEUROCHEMISTRY

Milestones in PD genetics

(2011) Thomas Gasser et al.   MOVEMENT DISORDERS

Milestones in Parkinson's disease-Clinical and pathologic features

(2011) Glenda Halliday et al.   MOVEMENT DISORDERS

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2

(2011) Xianming Deng et al.   Nature Chemical Biology

The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease

(2011) Zhihua Liu et al.   NATURE IMMUNOLOGY

Regulation of LRRK2 Expression Points to a Functional Role in Human Monocyte Maturation

(2011) Jonathan Thévenet et al.   PLoS One

Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization

(2010) Nicolas Dzamko et al.   BIOCHEMICAL JOURNAL

14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization

(2010) R. Jeremy Nichols et al.   BIOCHEMICAL JOURNAL

Genetic variability at the PARK16 locus

(2010) Arianna Tucci et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update

(2010) Karen Nuytemans et al.   HUMAN MUTATION

LRRK2 Is Involved in the IFN-  Response and Host Response to Pathogens

(2010) A. Gardet et al.   JOURNAL OF IMMUNOLOGY

The risk of Parkinson’s disease in type 1 Gaucher disease

(2010) Gilberto Bultron et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease

(2010) Byoung Dae Lee et al.   NATURE MEDICINE

Mechanisms of mitophagy

(2010) Richard J. Youle et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease

(2010) Mark R. Cookson   NATURE REVIEWS NEUROSCIENCE

Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2

(2010) H. Mortiboys et al.   NEUROLOGY

Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of  -synuclein, and apoptotic cell death in aged mice

(2010) Y. Tong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease

(2009) R. Jeremy Nichols et al.   BIOCHEMICAL JOURNAL

Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease

(2009) Wataru Satake et al.   NATURE GENETICS

Genome-wide association study reveals genetic risk underlying Parkinson's disease

(2009) Javier Simón-Sánchez et al.   NATURE GENETICS

Rab GTPases as coordinators of vesicle traffic

(2009) Harald Stenmark   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Genomewide Association Study of Leprosy

(2009) Fu-Ren Zhang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease

(2009) E. Sidransky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metabolomic Profiling in LRRK2-Related Parkinson's Disease

(2009) Krisztina K. Johansen et al.   PLoS One

A critical reappraisal of current staging of Lewy-related pathology in human brain

(2008) Kurt A. Jellinger   ACTA NEUROPATHOLOGICA

Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance

(2008) Laura Parkkinen et al.   ACTA NEUROPATHOLOGICA

Incidental Lewy Body Disease and Preclinical Parkinson Disease

(2008) Anthony DelleDonne et al.   ARCHIVES OF NEUROLOGY

Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2

(2008) Jason P. Covy et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The Gly2019Ser mutation in LRRK2is not fully penetrant in familial Parkinson's disease: the GenePD study

(2008) Jeanne C Latourelle et al.   BMC Medicine

Investigation of leucine-rich repeat kinase 2

(2008) Vasanti S. Anand et al.   FEBS Journal

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

(2008) Daniel G Healy et al.   LANCET NEUROLOGY

LRRK2 G2019S and R1441G mutations associated with Parkinson’s disease are common in the Basque Country, but relative prevalence is determined by ethnicity

(2008) A. Gorostidi et al.   NEUROGENETICS

Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease

(2008) K. Haugarvoll et al.   NEUROLOGY

Familial parkinsonism: Study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes

(2008) Kazuko Hasegawa et al.   PARKINSONISM & RELATED DISORDERS